Echinocandins for candidemia: a rational choice

Francesco Menichetti, Enrico Tagliaferri

DOI: https://doi.org/10.7175/rhc.v4i2S.872

Abstract

Among antifungal drugs, echinocandins (micafungin, caspofungin and anidulafungin) represent a rational choice for the first-line therapy of candidemia/invasive candidiasis in critically ill patients. Among other properties characterizing echinocandins, it’s important to emphasize the broad spectrum of activity, the fungicidal activity against the majority of Candida spp., and the activity against the biofilm. Furthermore, echinocandins show greater efficacy than conventional amphotericin B and fluconazole, and similar efficacy to liposomal amphotericin B (but they are less toxic). Finally, echinocandins are recommended at the highest level of evidence (AI) for the treatment of invasive candidiasis by IDSA and ESCMID guidelines.

Keywords

Echinocandins; Candidemia; Invasive candidiasis

Full Text

HTML PDF

References

  • Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35; http://dx.doi.org/10.1086/596757
  • Falcone M, Barzaghi N, Carosi G, et al.; Italian Study on Endocarditis. Candida infective endocarditis: report of 15 cases from a prospective multicenter study. Medicine (Baltimore) 2009; 88: 160-8; http://dx.doi.org/10.1097/MD.0b013e3181a693f8
  • Pfaller MA, Sheehan DJ, Rex JH. Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev 2004; 17: 268-80; http://dx.doi.org/10.1128/CMR.17.2.268-280.2004
  • Tumbarello M, Posteraro B, Trecarichi EM, et al. Biofilm production by Candida species and inadequate antifungal therapy as predictors of mortality for patients with candidemia. J Clin Microbiol 2007; 45: 1843-50; http://dx.doi.org/10.1128/JCM.00131-07
  • Cateau E, Berjeaud JM, Imbert C, et al. Possible role of azole and echinocandin lock solutions in the control of Candida biofilms associated with silicone. Int J Antimicrob Agents 2011; 37: 380-4; http://dx.doi.org/10.1016/j.ijantimicag.2010.12.016
  • Tascini C, Bongiorni MG, Tagliaferri E, et al. Micafungin for Candida albicans pacemaker-associated endocarditis: a case report and review of the literature. Mycopathologia 2013; 175: 129-34; http://dx.doi.org/10.1007/s11046-012-9591-2
  • Lortholary O, Desnos-Ollivier M, Sitbon K, et al. Recent exposure to caspofungin or fluconazole influences the epidemiology of candidemia: a prospective multicenter study involving 2,441 patients. Antimicrob Agents Chemother 2011; 55: 532-8; http://dx.doi.org/10.1128/AAC.01128-10
  • Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med 2002; 347: 2020-9; http://dx.doi.org/10.1056/NEJMoa021585
  • Betts RF, Nucci M, Talwar D, et al. A Multicenter, double-blind trial of a high-dose caspofungin treatment regimen versus a standard caspofungin treatment regimen for adult patients with invasive candidiasis. Clin Infect Dis 2009; 48: 1676-84; http://dx.doi.org/10.1086/598933
  • Reboli AC, Rotstein C, Pappas PG, et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007; 356: 2472-82; http://dx.doi.org/10.1056/NEJMoa066906
  • Kuse ER, Chetchotisakd P, da Cunha CA, et al. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 2007; 369: 1519-27; http://dx.doi.org/10.1016/S0140-6736(07)60605-9
  • Pappas PG, Rotstein CM, Betts RF, et al. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin Infect Dis 2007; 45: 883-93; http://dx.doi.org/10.1086/520980
  • Mycamine (micafungin sodium) – Summary of Product Characteristics
  • Cancidas (caspofungin) – Summary of Product Characteristics
  • Ecalta (anidulafungin) – Summary of Product Characteristics
  • Andes DR. Impact of treatment strategy on outcomes in patients with candidemia and other forms of invasive candidiasis. Clin Infect Dis 2012; 54: 1110-22; http://dx.doi.org/10.1093/cid/cis021
  • Cornely OA, Bassetti M, Calandra T, et al. ESCMID guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clin Microbiol Infect 2012; 18 Suppl 7: 19-37; http://dx.doi.org/10.1111/1469-0691.12039

Statistics

Abstract: 725 views
HTML: 1520 views
PDF: 1964 views

Refbacks

  • There are currently no refbacks.




© SEEd srl